Clinical trial
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who…
NCT00094029 · Pfizer, Industry · Approved for marketing
Key facts
| NCT number | NCT00094029 |
|---|---|
| Title | A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 |
| Official title | A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate |
| Lead sponsor | Pfizer, Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | Gastrointestinal Neoplasm |
| Intervention type | Drug |
| Interventions | Sutent |
| Start date | Sep 1, 2004 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Oct 11, 2004 |
| Last update posted | Mar 9, 2012 |
| Countries | Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany and 22 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: